MNPR - Why Is Cancer Focused Monopar Therapeutics Stock Trading Higher Today? | Benzinga
Monopar Therapeutics Inc (NASDAQ: MNPR) will present data from its ongoing Phase 1b open-label, dose-escalating trial of camsirubicin in patients with advanced soft tissue sarcoma later today at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting.
The Phase 1b clinical trial has enrolled 14 patients across five dose cohorts.
The trial is ongoing and in the fifth dose level cohort (650 mg/m2).
So far, 9 out of the 14 patients have had stable disease after camsirubicin treatment.
All patients ...